Genmab reported 787M in EBIT for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Agios Pharmaceuticals AGIO:US $ -91222000 5K
Alexion Pharmaceuticals ALXN:US $ 816.7M 185.9M
Amarin AMRN:US 8.77M 10.1M
Amgen AMGN:US $ 2333M 204M
AstraZeneca AZN:LN 1.4B 366M
Bayer BAYN:GR 1.64B 1.42B
Biomarin Pharmaceutical BMRN:US $ 13.86M 13.56M
Bluebird Bio BLUE:US $ -240791000 9.95M
Exelixis EXEL:US $ 123.01M 127.62M
Fresenius Medical Care FME:GR 402M 44M
Galapagos GLPG:NA -46750000 4.05M
Genmab GEN:DC 787M 255M
GlaxoSmithKline GSK:LN 1.96B 281M
GN Store Nord GN:DC 593M 119M
GRIFOLS GRF:SM 245.2M 40.86M
H. Lundbeck A/S LUN:DC 596M 286M
Hikma Pharmaceutical HIK:LN 280M 2M
Immunogen IMGN:US $ -27369000 1.55M
Insmed INSM:US $ -88566000 4.73M
Lonza Group LONN:SW 599M 271M
Merck MRK:GR 1.16B 63M
Novartis NOVN:VX 3.4B 415M
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Seattle Genetics SGEN:US $ -89603000 32.82M
William Demant Holding WDH:DC 1.59B 118M